A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate - PubMed (original) (raw)
A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate
J W Hodge et al. Int J Cancer. 1995.
Abstract
Prostate-specific antigen (PSA) is a serine protease secreted by prostatic epithelial cells and is widely used as a marker for prostate cancer. The tissue specificity of PSA makes it a potential target for active specific immunotherapy, especially in prostate cancer patients who have undergone prostatectomy and in whom the only PSA-expressing tissue in the body resides in metastatic deposits. We report here the cloning, construction and immunological consequences of immunization of rhesus monkeys with a recombinant vaccinia virus expressing human PSA (designated rV-PSA). The prostate gland of the rhesus is structurally and functionally similar to the human prostate. While rodent and other mammalian species do not share homology with human PSA, there is 94% homology between the amino acid sequences of rhesus and human PSA. Immunization of rhesus monkeys with wild-type vaccinia virus or rV-PSA elicited the usual low-grade constitutional symptoms of vaccinia virus infection. There was no evidence of any adverse effects in any immunized monkeys. A short-lived PSA-specific IgM antibody response was noted in all rV-PSA immunized monkeys regardless of dose level. All monkeys receiving the 10(8)pfu dose of rV-PSA demonstrated PSA-specific T-cell responses that were maintained up to 270 days. No differences in anti-PSA immune responses or toxicity were observed in animals that received prostatectomy prior to immunization. Our results thus demonstrate the safety and immunogenicity of rV-PSA in a non-human primate and have implications for potential specific immunotherapy protocols using PSA as a target.
Similar articles
- Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J, Kaufman H, Eggensperger D, Schlom J. Kantor J, et al. Cancer Res. 1992 Dec 15;52(24):6917-25. Cancer Res. 1992. PMID: 1458480 - Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.
Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, Weiner DB. Kim JJ, et al. Oncogene. 2001 Jul 27;20(33):4497-506. doi: 10.1038/sj.onc.1204542. Oncogene. 2001. PMID: 11494145 - A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. Eder JP, et al. Clin Cancer Res. 2000 May;6(5):1632-8. Clin Cancer Res. 2000. PMID: 10815880 Clinical Trial. - CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM, Karan D. Lubaroff DM, et al. Adv Drug Deliv Rev. 2009 Mar 28;61(3):268-74. doi: 10.1016/j.addr.2008.12.005. Epub 2009 Jan 7. Adv Drug Deliv Rev. 2009. PMID: 19166887 Review. - Prostate-specific antigen vaccines for prostate cancer.
Hörig H, Lee CS, Kaufman HL. Hörig H, et al. Expert Opin Biol Ther. 2002 Apr;2(4):395-408. doi: 10.1517/14712598.2.4.395. Expert Opin Biol Ther. 2002. PMID: 11955277 Review.
Cited by
- Vaccines as treatments for prostate cancer.
Rastogi I, Muralidhar A, McNeel DG. Rastogi I, et al. Nat Rev Urol. 2023 Sep;20(9):544-559. doi: 10.1038/s41585-023-00739-w. Epub 2023 Mar 6. Nat Rev Urol. 2023. PMID: 36879114 Free PMC article. Review. - Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter.
Wang G, Liu Y, Liu S, Lin Y, Hu C. Wang G, et al. Int J Mol Sci. 2022 Oct 21;23(20):12647. doi: 10.3390/ijms232012647. Int J Mol Sci. 2022. PMID: 36293504 Free PMC article. Review. - Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B, Guo ZS, Bartlett DL, Yan DZ, Schane CP, Thomas DL, Liu J, McFadden G, Shisler JL, Roy EJ. Tang B, et al. Clin Cancer Res. 2020 May 1;26(9):2216-2230. doi: 10.1158/1078-0432.CCR-18-3626. Epub 2020 Feb 4. Clin Cancer Res. 2020. PMID: 32019860 Free PMC article. - A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant.
Abdallah AO, Coleman H, Kamel M, Davis R, Landrum T, Spencer H, Mackintosh S, Mahmoud FA, Milojkovic N, Wicker C, Arnaoutakis K, Nakagawa M. Abdallah AO, et al. SAGE Open Med. 2018 Sep 17;6:2050312118800202. doi: 10.1177/2050312118800202. eCollection 2018. SAGE Open Med. 2018. PMID: 30245818 Free PMC article. - Oncolytic virotherapy for urological cancers.
Delwar Z, Zhang K, Rennie PS, Jia W. Delwar Z, et al. Nat Rev Urol. 2016 Jun;13(6):334-52. doi: 10.1038/nrurol.2016.84. Epub 2016 May 24. Nat Rev Urol. 2016. PMID: 27215429 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous